FDA Approves Incyte's Niktimvo for Chronic GVHD

Aug 14, 2024, 10:09 PM

The U.S. Food and Drug Administration (FDA) has approved Incyte Corporation's drug, Niktimvo™ (axatilimab-csfr), for the treatment of chronic graft-versus-host disease (GVHD). This condition is a potentially fatal complication that can occur after a stem cell transplant. The approval marks a significant advancement in the treatment options available for patients suffering from chronic GVHD. The drug, developed in collaboration with Syndax Pharmaceuticals, offers a new therapeutic option for managing this serious condition.